Skip to content
Annika Bansal – Lifestyle
Author:
NEKTAR THERAPEUTICS
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
July 21, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
May 27, 2026
←
Previous Page
1
2